Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Garrett Yam

Internal Medicine Redmond, WA Medical Doctor

NPI 1811146970 CMS profile 354902

2103 152Nd Ave Ne, Redmond, WA 98052

Open in the dashboard

General payments

$8,965

382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garrett Yam of Redmond, WA is reported in the CMS Open Payments database as having received $8,965 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,739 62
2024 General $1,461 51
2023 General $1,392 58
2022 General $1,551 55
2021 General $1,016 53
2020 General $991 53
2019 General $815 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garrett Yam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Garrett Yam were reported at $1,739. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Garrett Yam Internal Medicine median Middle half National median
2019 $815 $159 $48–$570 $163
2020 $991 $119 $33–$402 $114
2021 $1,016 $135 $37–$521 $132
2022 $1,551 $141 $42–$496 $149
2023 $1,392 $149 $45–$519 $160
2024 $1,461 $154 $47–$537 $164
2025 $1,739 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,568 84 payments
  2. Abbott Laboratories $1,193 42 payments
  3. Sekisui Diagnostics LLC $1,090 3 payments
  4. AbbVie, Inc. $551 25 payments
  5. Kowa Pharmaceuticals America, Inc. $538 25 payments
  6. Novo Nordisk Inc $475 30 payments
  7. IBSA Pharma Inc. $310 15 payments
  8. Pfizer Inc. $287 11 payments
  9. Amarin Pharma Inc. $247 13 payments
  10. Shield Therapeutics Inc $218 10 payments
  11. Other $2,488 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,875 379 payments
  2. Gift $1,090 3 payments
Products named General payments · program years 2019–2025
  1. FreeStyle Libre 3 $864 30 payments
  2. FARXIGA $656 32 payments
  3. BREZTRI $402 21 payments
  4. FreeStyle Libre 2 $328 12 payments
  5. Licart $310 15 payments
  6. Livalo $310 17 payments
  7. Ozempic $301 18 payments
  8. SYMBICORT $298 16 payments
  9. RYBELSUS $278 17 payments
  10. UBRELVY $265 12 payments
  11. Other $5,734 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record